The use of novel oral anticoagulants: The debate continues!

Blood Transfusion

Volumn 13, Issue 2, 2015, Pages 170-171

  Franchini, Massimo ^a   Velati, Claudio ^b,c  

^a CARLO POMA HOSPITAL   (Italy)

^b Transfusion Medicine and Immunohaematology Department of Bologna Metropolitan Area   (Italy)

^c Regione Emilia Romagna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; EDOXABAN; RIVAROXABAN; THROMBIN INHIBITOR;

DRUG BIOAVAILABILITY; EDITORIAL; GENETIC VARIABILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; SEVERE RENAL IMPAIRMENT; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 84927557449     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2015.0059-15     Document Type: Editorial

References (8)

1. Ageno W, Gallus AS, Wittkowsky A et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e44S-88S.
2. Franchini M, Mengoli C, Cruciani M et al. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost 2014;12:1480-7.
3. Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Intern Med 2009;20:562.
4. Prandoni P. Venous thromboembolism in 2013: the advent of the novel oral anticoagulants. Nat Rev Cardiol 2014;11:70-2.
5. Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e120S-51S.
6. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
7. Prandoni P. The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations. Blood Transfus 2015;13:178-80.
8. Riva N, Ageno W. Which patients with venous thromboembolism should receive non-vitamin-K antagonist oral anticoagulants? The majority. Blood Transfus 2015;13:181-3